[Treatment with new antitubercular agents].
D000995:Antitubercular Agents / Q000009:adverse effects / Q000627:therapeutic use*; D003523:Cycloserine / Q000627:therapeutic use; D004352:Drug Resistance, Microbial; D004357:Drug Synergism; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D006801:Humans; D009169:Mycobacterium tuberculosis / Q000187:drug effects; D010670:Phenylthiourea / Q000031:analogs & derivatives / Q000627:therapeutic use; D011718:Pyrazinamide / Q000627:therapeutic use; D012293:Rifampin / Q000627:therapeutic use; D013882:Thiosemicarbazones / Q000627:therapeutic use; D014376:Tuberculosis / Q000188:drug therapy*; D014756:Viomycin / Q000627:therapeutic use
D000995:Antitubercular Agents; D013882:Thiosemicarbazones; D011718:Pyrazinamide; D010670:Phenylthiourea; D004977:Ethambutol; D003523:Cycloserine; D005000:Ethionamide; D012293:Rifampin; D014756:Viomycin
Therapie mit neuen Tuberkulostatika.